About Cellanome
Cellanome is a company based in Palo Alto (United States) founded in 2020 by Mostafa Ronaghi.. Cellanome has raised $42.71 million across 2 funding rounds. Cellanome offers products and services including Automated Platform and Live Cell Assays. Cellanome operates in a competitive market with competitors including Cellworks, Tessera Therapeutics, Phase Genomics, Genuity Science and ICarbonX, among others.
- Headquarter Palo Alto, United States
- Founders Mostafa Ronaghi
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$42.71 M (USD)
in 2 rounds
-
Latest Funding Round
$40.66 M (USD), Series A
Mar 21, 2023
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellanome
Cellanome offers a comprehensive portfolio of products and services, including Automated Platform and Live Cell Assays. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables detailed study of cell behaviors and interactions at scale.
Facilitates iterative assays linking cell responses to perturbations.
Unlock access to complete
Unlock access to complete
Funding Insights of Cellanome
Cellanome has successfully raised a total of $42.71M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $40.66 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $40.7M
-
First Round
First Round
(05 Oct 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2023 | Amount | Series A - Cellanome | Valuation |
investors |
|
| Oct, 2021 | Amount | Seed - Cellanome | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Cellanome
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cellanome
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cellanome Comparisons
Competitors of Cellanome
Cellanome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellworks, Tessera Therapeutics, Phase Genomics, Genuity Science and ICarbonX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biosimulation platform developed for therapeutic design in life sciences.
|
|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| domain | founded_year | HQ Location |
AI-based omics data analysis solutions are provided to researchers.
|
|
| domain | founded_year | HQ Location |
Bioinformatics platforms are provided for health management and drug development.
|
|
| domain | founded_year | HQ Location |
Bioinformatics tools for genome sequencing data analysis are provided.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cellanome
Frequently Asked Questions about Cellanome
When was Cellanome founded?
Cellanome was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Cellanome located?
Cellanome is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Is Cellanome a funded company?
Cellanome is a funded company, having raised a total of $42.71M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.05M, raised on Oct 05, 2021.
What does Cellanome do?
Cellanome was founded in 2020 and is headquartered in Palo Alto, United States. A multi-omics platform is provided by the company for researchers, integrating synthetic biology and informatics approaches. Operations focus on handling omic data to support scientific analysis in the biotechnology sector. Services enable data processing and integration across various omics disciplines.
Who are the top competitors of Cellanome?
Cellanome's top competitors include Tessera Therapeutics, Phase Genomics and Cellworks.
What products or services does Cellanome offer?
Cellanome offers Automated Platform and Live Cell Assays.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.